News
All news from Vismederi Holding
New Publication: Advancing Vaccine Research with GVGH – A Novel Assay for Quantifying Anti-Vi IgG in Clinical Sera
VisMederi is pleased to announce the publishing of a collaborative study with GVGH (GSK Vaccines Institute for Global Health) that highlights a significant achievement in vaccine research. This recent study, published in Frontiers in Immunology, describes the...
The first workshop involving Trialect and the Vismederi Foundation is underway!
For those wishing to fully immerse themselves in the serological techniques required by regulatory agencies including the FDA, EMA, and PMD for the licensing and approval of viral vaccines, a 12-week program has been developed by Trialect and VisMederi Foundation....
VisMederi Foundation at the Bright-Night 2024
European Night of Female Researchers and Scientists in Tuscany is known as Bright Night. Whether geographic, historical, artistic, literary, scientific, or psychological, the 2024 Bright Night' s focus was travel. Bright Night pairs the word night with the...
VisMederi will be present at the World Vaccine Congress Europe 2024 in Barcelona
VisMederi will be attending the World Vaccine Congress Europe 2024, taking place from October 28th to 31st at Fira de Barcelona, Montjuïc. The significance of this event brings together leading minds from the life sciences and public health fields to discuss the...
Collaboration Agreement Signed Between Trialect Inc. USA and Fondazione VisMederi
Fondazione VisMederi has signed an agreement with Trialect Inc., USA, for the program entitled “Trialect Global Medical Education Program.” This initiative aims to provide short-term training and education for biomedical scientists and physicians to enhance the...
A new study suggests that antibodies produced by vaccinia-based vaccines may neutralize the Monkeypox virus
A new study suggests that antibodies produced by vaccinia-based vaccines may neutralize the Monkeypox virus, suggesting potential cross-protection against new threats. The findings emphasize VisMederi's capability to aid in vaccine development and research efforts...